Is CTXR or MCRB more profitable?

Citius Pharmaceuticals' return on equity of -61.09% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Citius Pharmaceuticals N/A -61.09% -35.36% Seres Therapeutics N/A -130.29% -35.35%

Does the media favor CTXR or MCRB?

In the previous week, Seres Therapeutics had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 4 mentions for Seres Therapeutics and 2 mentions for Citius Pharmaceuticals. Seres Therapeutics' average media sentiment score of 0.81 beat Citius Pharmaceuticals' score of -0.17 indicating that Seres Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Seres Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TCRX or CTXR?

In the previous week, TScan Therapeutics and TScan Therapeutics both had 2 articles in the media. TScan Therapeutics' average media sentiment score of 0.84 beat Citius Pharmaceuticals' score of -0.17 indicating that TScan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CTXR or TCRT?

Citius Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 792.86%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, CTXR or TCRT?

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Pharmaceuticals N/A N/A -$37.43M -$2.13 N/A Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A

Is CTXR or TCRT more profitable?

Citius Pharmaceuticals' return on equity of -61.09% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Citius Pharmaceuticals N/A -61.09% -35.36% Alaunos Therapeutics N/A -165.94% -123.50%

Which has preferable earnings & valuation, OKYO or CTXR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$4.71M N/A N/A Citius Pharmaceuticals N/A N/A -$37.43M -$2.13 N/A

Is OKYO or CTXR more profitable?

OKYO Pharma's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A Citius Pharmaceuticals N/A -61.09% -35.36%

Do analysts prefer BYSI or CTXR?

Citius Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 792.86%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is BYSI or CTXR more profitable?

BeyondSpring's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% Citius Pharmaceuticals N/A -61.09% -35.36%

Does the media refer more to BYSI or CTXR?

In the previous week, BeyondSpring had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 4 mentions for BeyondSpring and 2 mentions for Citius Pharmaceuticals. BeyondSpring's average media sentiment score of 0.73 beat Citius Pharmaceuticals' score of -0.17 indicating that BeyondSpring is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeyondSpring 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Citius Pharmaceuticals (CTXR) Competitors

$0.56 -0.03 (-5.00%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$0.57 +0.01 (+2.50%)

As of 06/5/2026 07:22 PM Eastern

Compare

CTXR vs. MCRB, TCRX, TCRT, OKYO, and BYSI

Should you buy Citius Pharmaceuticals stock or one of its competitors? MarketBeat compares Citius Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Citius Pharmaceuticals include Seres Therapeutics (MCRB), TScan Therapeutics (TCRX), Alaunos Therapeutics (TCRT), OKYO Pharma (OKYO), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry.

How does Citius Pharmaceuticals compare to Seres Therapeutics?

Citius Pharmaceuticals (NASDAQ:CTXR) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

In the previous week, Seres Therapeutics had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 4 mentions for Seres Therapeutics and 2 mentions for Citius Pharmaceuticals. Seres Therapeutics' average media sentiment score of 0.81 beat Citius Pharmaceuticals' score of -0.17 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Seres Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 5.0% of Citius Pharmaceuticals shares are held by insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Citius Pharmaceuticals currently has a consensus price target of $5.00, indicating a potential upside of 792.86%. Seres Therapeutics has a consensus price target of $22.00, indicating a potential upside of 231.83%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Citius Pharmaceuticals is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Seres Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Seres Therapeutics has higher revenue and earnings than Citius Pharmaceuticals. Seres Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A
Seres Therapeutics	$1.15M	55.98	$5.70M	-$5.17	N/A

Citius Pharmaceuticals has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.13, meaning that its stock price is 87% less volatile than the broader market.

Citius Pharmaceuticals' return on equity of -61.09% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-61.09%	-35.36%
Seres Therapeutics	N/A	-130.29%	-35.35%

Summary

Citius Pharmaceuticals and Seres Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

In the previous week, TScan Therapeutics and TScan Therapeutics both had 2 articles in the media. TScan Therapeutics' average media sentiment score of 0.84 beat Citius Pharmaceuticals' score of -0.17 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

TScan Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

TScan Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 511.06%. Citius Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 792.86%. Given Citius Pharmaceuticals' higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than TScan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Citius Pharmaceuticals has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. Citius Pharmaceuticals' return on equity of -61.09% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

Citius Pharmaceuticals has lower revenue, but higher earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	6.22	-$129.77M	-$0.96	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

Summary

TScan Therapeutics beats Citius Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Alaunos Therapeutics?

Citius Pharmaceuticals (NASDAQ:CTXR) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Citius Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 792.86%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Citius Pharmaceuticals has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.07, indicating that its share price is 207% less volatile than the broader market.

Citius Pharmaceuticals' return on equity of -61.09% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-61.09%	-35.36%
Alaunos Therapeutics	N/A	-165.94%	-123.50%

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A

16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 5.0% of Citius Pharmaceuticals shares are held by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Citius Pharmaceuticals had 2 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 2 mentions for Citius Pharmaceuticals and 0 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.00 beat Citius Pharmaceuticals' score of -0.17 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Citius Pharmaceuticals	Neutral
Alaunos Therapeutics	Neutral

Summary

Citius Pharmaceuticals beats Alaunos Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to OKYO Pharma?

OKYO Pharma (NASDAQ:OKYO) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by company insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

OKYO Pharma has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

OKYO Pharma presently has a consensus price target of $6.33, indicating a potential upside of 290.95%. Citius Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 792.86%. Given Citius Pharmaceuticals' higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Citius Pharmaceuticals had 2 more articles in the media than OKYO Pharma. MarketBeat recorded 2 mentions for Citius Pharmaceuticals and 0 mentions for OKYO Pharma. Citius Pharmaceuticals' average media sentiment score of -0.17 beat OKYO Pharma's score of -0.54 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
OKYO Pharma	Negative
Citius Pharmaceuticals	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

OKYO Pharma's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

Summary

OKYO Pharma beats Citius Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

BeyondSpring has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

In the previous week, BeyondSpring had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 4 mentions for BeyondSpring and 2 mentions for Citius Pharmaceuticals. BeyondSpring's average media sentiment score of 0.73 beat Citius Pharmaceuticals' score of -0.17 indicating that BeyondSpring is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeyondSpring	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by company insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BeyondSpring's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

Citius Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 792.86%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

BeyondSpring has higher revenue and earnings than Citius Pharmaceuticals. BeyondSpring is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	40.18	-$1.01M	-$0.14	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

Summary

BeyondSpring beats Citius Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Citius Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTXR vs. The Competition

Export

Metric	Citius Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.37M	$2.96B	$6.66B	$11.99B
Dividend Yield	N/A	1.70%	2.67%	5.56%
P/E Ratio	-0.26	18.12	24.03	23.62
Price / Sales	N/A	292.63	518.10	111.56
Price / Cash	N/A	56.17	26.99	37.22
Price / Book	0.13	3.83	10.24	6.66
Net Income	-$37.43M	$75.85M	$3.57B	$337.55M
7 Day Performance	-14.49%	-1.85%	-1.28%	-2.52%
1 Month Performance	-14.39%	-5.62%	1.38%	-0.03%
1 Year Performance	-34.20%	14.98%	23.93%	25.34%

Citius Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTXR Citius Pharmaceuticals	2.9831 of 5 stars	$0.56 -5.0%	$5.00 +792.9%	-34.2%	$15.37M	N/A	N/A	20	Analyst Downgrade Gap Up
MCRB Seres Therapeutics	2.0767 of 5 stars	$7.64 +4.4%	$22.00 +188.0%	-19.4%	$70.89M	$1.15M	N/A	330	News Coverage Analyst Upgrade Gap Up
TCRX TScan Therapeutics	3.138 of 5 stars	$1.01 -6.5%	$6.00 +494.1%	-45.5%	$70.58M	$10.32M	N/A	100
TCRT Alaunos Therapeutics	0.7107 of 5 stars	$2.87 +0.7%	N/A	-24.8%	$69.60M	N/A	N/A	40	Gap Up
OKYO OKYO Pharma	2.4979 of 5 stars	$1.71 -0.3%	$6.33 +270.4%	-14.7%	$69.55M	N/A	N/A	7	Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTXR) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Citius Pharmaceuticals (CTXR) Competitors

CTXR vs. MCRB, TCRX, TCRT, OKYO, and BYSI

How does Citius Pharmaceuticals compare to Seres Therapeutics?

Summary

How does Citius Pharmaceuticals compare to TScan Therapeutics?

Summary

How does Citius Pharmaceuticals compare to Alaunos Therapeutics?

Summary

How does Citius Pharmaceuticals compare to OKYO Pharma?

Summary

How does Citius Pharmaceuticals compare to BeyondSpring?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR vs. The Competition

Citius Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Citius Pharmaceuticals (CTXR) Competitors

CTXR vs. MCRB, TCRX, TCRT, OKYO, and BYSI

How does Citius Pharmaceuticals compare to Seres Therapeutics?

Does the media favor CTXR or MCRB?

Do insiders & institutionals hold more shares of CTXR or MCRB?

Do analysts prefer CTXR or MCRB?

Which has stronger earnings and valuation, CTXR or MCRB?

Which has more risk & volatility, CTXR or MCRB?

Is CTXR or MCRB more profitable?

Summary

How does Citius Pharmaceuticals compare to TScan Therapeutics?

Does the media favor TCRX or CTXR?

Which has more risk & volatility, TCRX or CTXR?

Do institutionals and insiders hold more shares of TCRX or CTXR?

Do analysts prefer TCRX or CTXR?

Is TCRX or CTXR more profitable?

Which has preferable valuation & earnings, TCRX or CTXR?

Summary

How does Citius Pharmaceuticals compare to Alaunos Therapeutics?

Do analysts rate CTXR or TCRT?

Which has more risk & volatility, CTXR or TCRT?

Is CTXR or TCRT more profitable?

Which has better earnings & valuation, CTXR or TCRT?

Do institutionals and insiders believe in CTXR or TCRT?

Does the media favor CTXR or TCRT?

Summary

How does Citius Pharmaceuticals compare to OKYO Pharma?

Do insiders & institutionals have more ownership in OKYO or CTXR?

Which has more risk and volatility, OKYO or CTXR?

Do analysts rate OKYO or CTXR?

Does the media favor OKYO or CTXR?

Which has preferable earnings & valuation, OKYO or CTXR?

Is OKYO or CTXR more profitable?

Summary

How does Citius Pharmaceuticals compare to BeyondSpring?

Which has more volatility & risk, BYSI or CTXR?

Does the media refer more to BYSI or CTXR?

Do insiders and institutionals believe in BYSI or CTXR?

Is BYSI or CTXR more profitable?

Do analysts prefer BYSI or CTXR?

Which has better earnings and valuation, BYSI or CTXR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR vs. The Competition

Citius Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools